Atlantic Edge Private Wealth Management’s Sinovac Biotech, Ltd SVA Stock Holding History

Atlantic Edge Private Wealth Management’s Portfolio SVA Stock Details SVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$0	Hold	1,000	–	–	﹤0.01%	645
2026 Q1	$0	Hold	1,000	–	–	﹤0.01%	626
2025 Q4	$0	Hold	1,000	–	–	﹤0.01%	605
2025 Q3	$0	Hold	1,000	–	–	﹤0.01%	559
2025 Q2	$0	Buy	+1,000	New	–	﹤0.01%	530
2024 Q3	–	Sell	-1,000	Closed	–	–	517
2024 Q2	$0	Hold	1,000	–	–	﹤0.01%	518
2024 Q1	$0	Buy	+1,000	New	–	﹤0.01%	510

Other funds holding SVA

NAH

Neumann Advisory (HK) Central, Hong Kong $356M AUM 37.48% 1-Year Est. Return

Atlantic Edge Private Wealth Management's SVA Position: Q2 2026 in Review

Atlantic Edge Private Wealth Management held its Sinovac Biotech, Ltd (SVA) position steady in Q2 2026 at 1,000 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #645.

Atlantic Edge Private Wealth Management first reported a position in SVA in Q1 2024 and has held it in 7 quarters since. 4 funds tracked by Wall St. Rank hold SVA as of Q2 2026.

Atlantic Edge Private Wealth Management held 1,000 shares of Sinovac Biotech, Ltd worth $0 as of Q2 2026.
Atlantic Edge Private Wealth Management left its Sinovac Biotech, Ltd share count unchanged in Q2 2026.
Sinovac Biotech, Ltd made up ﹤0.01% of Atlantic Edge Private Wealth Management's portfolio in Q2 2026, its #645 holding.
Atlantic Edge Private Wealth Management first reported a position in Sinovac Biotech, Ltd in Q1 2024 and has held it in 7 quarters since.
4 funds tracked by Wall St. Rank held Sinovac Biotech, Ltd as of Q2 2026.

Based on Atlantic Edge Private Wealth Management's 13F filing for Q2 2026, filed 23 Jul 2026.